SEC Form 4

 \Box

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5	S
obligations may continue. See Instruction 1(b).	

TATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and A Lucchese	ddress of Reporting	g Person [*]	2. Issuer Name and Ticker or Trading Symbol Inari Medical, Inc. [NARI]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Lucchese	<u>Cyntina L</u>			X	Director	10% Owner				
C/O INARI MEDICAL, INC. 6001 OAK CANYON			3. Date of Earliest Transaction (Month/Day/Year) 05/26/2022		Officer (give title below)	Other (specify below)				
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	ng (Check Applicable					
				X	Form filed by One Reporting Person					
IRVINE	CA	92618			Form filed by More th Person	an One Reporting				
(City)	(State)	(Zip)								
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)	ction				Securities Beneficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	05/26/2022		Α		2,420 ⁽¹⁾	Α	\$ <mark>0</mark>	31,891	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)													
2. Conversion or Exercise	3. Transaction Date (Month/Dav/Year)	3A. Deemed Execution Date, if any	4. Transaction Code (Instr.	of	6. Date Exercisable and Expiration Date (Month/Dav/Year)	7. Title and Amount of Securities	8. Price of Derivative Security	9. Number of derivative Securities	10. Ownership Form:	11. Nature of Indirect Beneficial			

Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	ercise (Month/Day/Year) of ative	Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)				Expiration Date (Month/Day/Year)		Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					

Explanation of Responses:

1. Title of

1. Represents RSUs granted on May 26, 2022, to the Reporting Person that vest in full on the earlier to occur of (i) the one-year anniversary of the grant date and (ii) the date of the 2023 annual meeting.

/s/ Angela Ahmad, attorneyin-fact for Cynthia Lucchese

05/27/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.